Skip to main content
SpringerLink
Log in

Neue Medikamente zur Behandlung der Tuberkulose

New drugs for treatment of tuberculosis

  • Schwerpunkt: Tuberkulose
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Neue antituberkulös wirksame Medikamente werden aus zwei wichtigen Gründen benötigt. Zum einen wäre es wünschenswert, die Therapiedauer von jetzt noch mindestens 6 Monaten zu verkürzen, zum anderen bedarf es neuer Medikamente zur Behandlung multiresistenter M ycobacterium- tuberculosis-Stämme. Erstmals seit 1960 wurden 2014 mit Bedaquilin und Delamanid zwei neue Medikamente zur Behandlung der multiresistenten Tuberkulose zugelassen. Enttäuscht haben hingegen die Versuche, die Therapiedauer durch den Einsatz von Fluorchinolonen auf 4 Monate zu verkürzen. Weitere neue Medikamente befinden sich zurzeit in Phase-II- und Phase-III-Studien, sodass in wenigen Jahren mit neuen Therapieoptionen gerechnet werden kann.

Abstract

New effective drugs for the treatment of tuberculosis (TB) are necessary for two main reasons: firstly, it would be desirable to reduce the duration of TB treatment from 6 to 4 months and secondly, new drugs are urgently needed for the treatment of multidrug-resistant strains of Mycobacterium tuberculosis. For the first time since 1960 the two new drugs bedaquiline and delamanid were approved and licensed in 2014 for the treatment of multidrug-resistant M. tuberculosis; however, efforts to reduce the duration of treatment to 4 months using fluoroquinolones have not been successful. Further new drugs are currently in phase 2 and phase 3 studies; therefore, new treatment options can be expected within the next few years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3(10 Suppl 2):S231–79

    CAS  PubMed  Google Scholar 

  2. World Health Organization (2014) Global tuberculosis report 2013. World Health Organization, Geneva

    Google Scholar 

  3. Falzon D et al (2011) WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38(3):516–528

    Article  CAS  PubMed  Google Scholar 

  4. Frieden TR et al (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328(8):521–526

    Article  CAS  PubMed  Google Scholar 

  5. Van Deun A et al (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182(5):684–692

    Article  PubMed  Google Scholar 

  6. Gillespie SH et al (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371(17):1577–1587

    Article  PubMed Central  PubMed  Google Scholar 

  7. Merle CS et al (2014) A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371(17):1588–1598

    Article  PubMed  Google Scholar 

  8. Dawson R et al (2015) Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385(9979):1738–1747

    Article  CAS  PubMed  Google Scholar 

  9. Lee M et al (2012) Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367(16):1508–1518

    Article  CAS  PubMed  Google Scholar 

  10. Tang S et al (2015) Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 45(1):161–170

    Article  CAS  PubMed  Google Scholar 

  11. Koh WJ et al (2009) Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64(2):388–391

    Article  CAS  PubMed  Google Scholar 

  12. Weiss T et al (2015) Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 45(1):285–287

    Article  CAS  PubMed  Google Scholar 

  13. Mair SJ, L.K. (2006) A phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of single and multiple oral doses of spray-dried OPC-67683 in healthy male and female subjects. Otsuka Study No. 242-05-101, Charles River Study No. 018044, Charles River Report No. 26515

  14. Matsumoto M et al (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3(11):e466

    Article  PubMed Central  PubMed  Google Scholar 

  15. Sasaki H et al (2006) Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem 49(26):7854–7860

    Article  CAS  PubMed  Google Scholar 

  16. Gler MT et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366(23):2151–2160

    Article  CAS  PubMed  Google Scholar 

  17. Skripconoka V et al (2013) Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41(6):1393–1400

    Article  PubMed Central  PubMed  Google Scholar 

  18. Andries K et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223–227

    Article  CAS  PubMed  Google Scholar 

  19. Diacon AH et al (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360(23):2397–2405

    Article  CAS  PubMed  Google Scholar 

  20. Diacon AH et al (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371(8):723–732

    Article  PubMed  Google Scholar 

  21. Diacon AH et al (2012) Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56(6):3027–3031

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. https://clinicaltrials.gov/ct2/show/NCT01424670?term=delamanid&rank=3. Zugegriffen: 12.8.2015

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg, Elise-Averdieck-Str. 17, 27356, Rotenburg, Deutschland

    T. Schaberg

Authors
  1. T. Schaberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Schaberg.

Ethics declarations

Interessenkonflikt

T. Schaberg weist auf folgende Beziehung hin: T. Schaberg gibt an, die Firma Otsuka 2013 im Rahmen des Zulassungsverfahrens von Delamanid bei der European Medicines Agency (EMA)‎ beraten zu haben.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Redaktion

B. Salzberger, Regensburg

T. Welte, Hannover

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schaberg, T. Neue Medikamente zur Behandlung der Tuberkulose. Internist 57, 136–141 (2016). https://doi.org/10.1007/s00108-015-0011-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-015-0011-9

Schlüsselwörter

Keywords

Search

Navigation